Rescreening of persons with a negative colonoscopy result: results from a microsimulation model
- PMID: 23128861
- PMCID: PMC3515652
- DOI: 10.7326/0003-4819-157-9-201211060-00005
Rescreening of persons with a negative colonoscopy result: results from a microsimulation model
Abstract
Background: Persons with a negative result on screening colonoscopy are recommended to repeat the procedure in 10 years.
Objective: To assess the effectiveness and costs of colonoscopy versus other rescreening strategies after an initial negative colonoscopy result.
Design: Microsimulation model.
Data sources: Literature and data from the Surveillance, Epidemiology, and End Results program.
Target population: Persons aged 50 years who had no adenomas or cancer detected on screening colonoscopy.
Time horizon: Lifetime.
Perspective: Societal.
Intervention: No further screening or rescreening starting at age 60 years with colonoscopy every 10 years, annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal immunochemical testing (FIT), or computed tomographic colonography (CTC) every 5 years.
Outcome measures: Lifetime cases of colorectal cancer, life expectancy, and lifetime costs per 1000 persons, assuming either perfect or imperfect adherence.
Results of base-case analysis: Rescreening with any method substantially reduced the risk for colorectal cancer compared with no further screening (range, 7.7 to 12.6 lifetime cases per 1000 persons [perfect adherence] and 17.7 to 20.9 lifetime cases per 1000 persons [imperfect adherence] vs. 31.3 lifetime cases per 1000 persons with no further screening). In both adherence scenarios, the differences in life-years across rescreening strategies were small (range, 30 893 to 30 902 life-years per 1000 persons [perfect adherence] vs. 30 865 to 30 869 life-years per 1000 persons [imperfect adherence]). Rescreening with HSFOBT, FIT, or CTC had fewer complications and was less costly than continuing colonoscopy.
Results of sensitivity analysis: Results were sensitive to test-specific adherence rates.
Limitation: Data on adherence to rescreening were limited.
Conclusion: Compared with the currently recommended strategy of continuing colonoscopy every 10 years after an initial negative examination, rescreening at age 60 years with annual HSFOBT, annual FIT, or CTC every 5 years provides approximately the same benefit in life-years with fewer complications at a lower cost. Therefore, it is reasonable to use other methods to rescreen persons with negative colonoscopy results.
Primary funding source: National Cancer Institute.
Figures
Comment in
-
After a negative screening colonoscopy, a microsimulation model shows that currently recommended strategies are equally effective for rescreening.Evid Based Med. 2013 Oct;18(5):199-200. doi: 10.1136/eb-2012-101176. Epub 2013 Feb 6. Evid Based Med. 2013. PMID: 23389086 No abstract available.
Similar articles
-
Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population.J Natl Cancer Inst. 2010 Aug 18;102(16):1238-52. doi: 10.1093/jnci/djq242. Epub 2010 Jul 27. J Natl Cancer Inst. 2010. PMID: 20664028 Free PMC article.
-
Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.JAMA. 2016 Jun 21;315(23):2595-609. doi: 10.1001/jama.2016.6828. JAMA. 2016. PMID: 27305518 Free PMC article.
-
Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.Ann Intern Med. 2017 Oct 17;167(8):544-554. doi: 10.7326/M16-2891. Epub 2017 Oct 3. Ann Intern Med. 2017. PMID: 28973514
-
Colorectal Cancer Screening: An Updated Decision Analysis for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 May. Report No.: 20-05271-EF-2. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 May. Report No.: 20-05271-EF-2. PMID: 34097370 Free Books & Documents. Review.
-
An international review of the main cost-effectiveness drivers of virtual colonography versus conventional colonoscopy for colorectal cancer screening: is the tide changing due to adherence?Eur J Radiol. 2013 Nov;82(11):e629-36. doi: 10.1016/j.ejrad.2013.07.019. Epub 2013 Aug 12. Eur J Radiol. 2013. PMID: 23938237 Review.
Cited by
-
Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening in Patients Who Are Unscreened.JAMA Netw Open. 2023 Nov 1;6(11):e2343392. doi: 10.1001/jamanetworkopen.2023.43392. JAMA Netw Open. 2023. PMID: 37971743 Free PMC article.
-
Sequentially calibrating a Bayesian microsimulation model to incorporate new information and assumptions.BMC Med Inform Decis Mak. 2022 Jan 12;22(1):12. doi: 10.1186/s12911-021-01726-0. BMC Med Inform Decis Mak. 2022. PMID: 35022005 Free PMC article.
-
Detection of Postcolonoscopy Colorectal Neoplasia by Multi-target Stool DNA.Clin Transl Gastroenterol. 2021 Jun 18;12(6):e00375. doi: 10.14309/ctg.0000000000000375. Clin Transl Gastroenterol. 2021. PMID: 34140458 Free PMC article.
-
Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.Health Technol Assess. 2020 Nov;24(66):1-332. doi: 10.3310/hta24660. Health Technol Assess. 2020. PMID: 33252328 Free PMC article.
-
Validation of Colorectal Cancer Models on Long-term Outcomes from a Randomized Controlled Trial.Med Decis Making. 2020 Nov;40(8):1034-1040. doi: 10.1177/0272989X20961095. Epub 2020 Oct 20. Med Decis Making. 2020. PMID: 33078673 Free PMC article. Clinical Trial.
References
-
- Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603–7. - PubMed
-
- Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624–33. - PubMed
-
- Kronborg O, Jorgensen OD, Fenger C, Rasmussen M. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol. 2004;39(9):846–51. - PubMed
-
- Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91(5):434–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials